Department of Biostatistics, University of Liverpool, Liverpool, L69 3GB, UK.
Cochrane Editorial Unit, London, SW1Y 4QX, UK.
Syst Rev. 2018 Nov 20;7(1):204. doi: 10.1186/s13643-018-0861-z.
Treatment with anti-tuberculosis drugs may cause patients to experience serious adverse effects. Genetic factors, such as polymorphisms of CYP genes, may increase the likelihood of a patient experiencing such adverse drug reactions. In this systematic review and meta-analysis, we synthesised evidence for associations between CYP genetic variants and anti-tuberculosis drug-related toxicity outcomes.
We searched MEDLINE, PubMed, EMBASE, BIOSIS and Web of Science to identify relevant studies. We performed meta-analyses to obtain an effect estimate for each genetic variant on each outcome, and stratified all analyses by country. We qualitatively assessed the methodological quality of the included studies.
We included data from 28 distinct cohorts of patients in the review. We identified many areas of concern with regard to the quality of included studies. Patients with homozygous mutant-type or heterozygous genotype at the CYP2E1 RsaI polymorphism were significantly less likely to experience hepatotoxicity than patients with homozygous wild-type genotype (odds ratio [OR] = 0.75, 95% confidence interval [CI] 0.56-1.00; p = 0.047, I = 58.2%). No significant differences were observed for the CYP2E1 DraI and PstI polymorphisms. For the 96-bp deletion-insertion single-nucleotide polymorphism (SNP) of the CYP2E1 gene, homozygous mutant-type significantly increased hepatotoxicity risk compared with homozygous wild-type (OR = 8.20, 95% CI 1.38-48.68, I = 0%); no significant difference was observed for heterozygous genotype compared with homozygous wild-type (OR = 0.77, 95% CI 0.19-3.21, I = 0%).
Generally, we identified that coverage of the association between SNPs of CYP genes and anti-tuberculosis drug-related toxicity outcomes is incomplete. We observed significant associations between the RsaI and 96-bp deletion-insertion SNPs of the CYP2E1 gene and anti-tuberculosis drug-related hepatotoxicity. We were unable to comment on the impact of ethnicity on the investigated associations, as information on participants' ethnicity was sparsely reported in the included studies.
PROSPERO registration number: CRD42017068448.
抗结核药物治疗可能会导致患者出现严重的不良反应。遗传因素,如 CYP 基因的多态性,可能会增加患者发生此类药物不良反应的可能性。在本系统评价和荟萃分析中,我们综合了 CYP 遗传变异与抗结核药物相关毒性结局之间关联的证据。
我们检索了 MEDLINE、PubMed、EMBASE、BIOSIS 和 Web of Science,以确定相关研究。我们进行了荟萃分析,以获得每种遗传变异对每种结局的效应估计值,并按国家对所有分析进行分层。我们定性评估了纳入研究的方法学质量。
我们在综述中纳入了来自 28 个不同患者队列的数据。我们发现,纳入研究的质量存在许多令人关注的问题。CYP2E1 RsaI 多态性纯合突变型或杂合基因型患者发生肝毒性的可能性明显低于纯合野生型患者(比值比[OR] = 0.75,95%置信区间[CI] 0.56-1.00;p = 0.047,I = 58.2%)。CYP2E1 DraI 和 PstI 多态性无显著差异。对于 CYP2E1 基因的 96-bp 缺失-插入单核苷酸多态性(SNP),与纯合野生型相比,纯合突变型显著增加肝毒性风险(OR = 8.20,95%CI 1.38-48.68,I = 0%);与纯合野生型相比,杂合基因型无显著差异(OR = 0.77,95%CI 0.19-3.21,I = 0%)。
总体而言,我们发现 CYP 基因 SNP 与抗结核药物相关毒性结局之间关联的覆盖范围不完整。我们观察到 CYP2E1 基因的 RsaI 和 96-bp 缺失-插入 SNP 与抗结核药物相关肝毒性之间存在显著关联。由于纳入研究中关于参与者种族的信息报道很少,我们无法就种族对所研究关联的影响发表评论。
PROSPERO 注册号:CRD42017068448。